Product Description
GL-2 Molecule (Prescription Only)
Available in 10mg and 50mg Total Dose Vials
Dual-Incretin Therapy for Advanced Weight Loss, Blood Sugar Control & Metabolic Optimization
Formulations (All at 10mg / 1mL Concentration)
-
GL-2 Core 10: 1mL vial containing 10mg total GL-2
-
GL-2 Core 50: 5mL vial containing 50mg total GL-2
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-2 Therapy?
GL-2 is a prescription dual-incretin therapy that activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. These two metabolic pathways work synergistically to regulate appetite, improve insulin sensitivity, enhance satiety, and drive substantial fat loss.
By engaging both incretin systems simultaneously, GL-2 therapy offers greater metabolic impact than single-pathway GL-1 therapy alone and is widely used under clinical supervision for patients seeking more aggressive weight-loss and metabolic optimization.
All GL-2 products provided by PROpeptides require a clinical consultation and prescription from a licensed providerprior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Dual Incretin Activation for Enhanced Fat Loss
GL-2 activates both GLP-1 and GIP receptors, producing complementary effects on appetite suppression, satiety signaling, and energy regulation—resulting in accelerated and sustained fat loss.
SURMOUNT-1 Trial (NEJM, 2022)
– Demonstrated up to 22.5% total body-weight reduction over 72 weeks with dual-incretin therapy at higher doses.
🩸 Blood Sugar Control & Insulin Sensitivity
Dual incretin signaling improves glucose-dependent insulin secretion while reducing inappropriate glucagon release, supporting stable blood sugar control with low hypoglycemia risk.
SURPASS-2 Trial (Lancet, 2021)
– Showed superior HbA1c reduction and weight loss compared to single-pathway GL-1 therapy in patients with metabolic disease.
🧠 Appetite Regulation & Craving Suppression
GL-2 therapy slows gastric emptying, reduces reward-driven eating behavior, and enhances central nervous system satiety signaling.
Min et al., 2020
– Demonstrated modulation of appetite-related neural pathways with dual-incretin activation in both human and preclinical models.
💪 Lean Mass Preservation During Weight Loss
Despite significant fat loss, dual-incretin therapy has been shown to preserve lean muscle mass when paired with adequate protein intake and resistance training.
Heymsfield et al., 2023 (Obesity)
– Lean mass loss was minimized in patients undergoing substantial weight reduction with dual-incretin–based protocols.
⚕️ Clinical Access & Consultation Required
GL-2 therapy is prescription-only and will not be shipped without provider approval.
✔ Telehealth evaluation or established prescription required
✔ Lab testing may be requested (HbA1c, fasting glucose, IGF-1, lipid panel)
✔ Individualized prescription and titration plan
✔ Ongoing provider guidance and follow-up support
💉 Dosing Protocol (Applies to All GL-2 Variants)
Each vial provides 10mg GL-2 per 1mL of solution. Vial size determines total available dose.
| Variant | Volume | Total GL-2 | Estimated Duration |
|---|---|---|---|
| GL-2 Core 10 | 1 mL | 10 mg | ~2–4 weeks |
| GL-2 Core 50 | 5 mL | 50 mg | ~8–12+ weeks |
Typical Starting Dose: 20 units weekly (2 mg)
Titration Strategy:
• Increase by 10 units (1 mg) only after two consecutive weeks with no weight loss and no side effects
• Reduce dose by 10 units if side effects occur, then resume titration as tolerated
Typical Max Dose: 50–60 units weekly (5–6 mg), provider-directed
Route: Subcutaneous injection (abdomen or flank)
Duration: Weekly dosing for 3–6+ months
Stack Compatibility: Commonly paired with KPV, GHK-Cu, or Tesamorelin for inflammation control, body-composition support, and metabolic longevity
📦 What’s Included With Every Order
✔ 1 × GL-2 Molecule vial (Core 10 or Core 50)
✔ Pre-measured bacteriostatic water
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing & titration guide
✔ Telehealth consultation & provider oversight
Need Assistance?
Email: Admin@Propeptides.com
Call/Text: 480-400-6225
🛡️ Next-Level Fat Loss. Dual-Pathway Precision. Clinical Oversight.
GL-2 Core Therapy is designed for patients who need more than foundational GL-1 support. By activating two complementary incretin pathways, GL-2 delivers deeper metabolic change under structured medical supervision.
Start with GL-2 Core 10.
Commit long-term with GL-2 Core 50.
All options include medical consultation and individualized dosing guidance.
Directions For Use
GL-2 Molecule (Prescription Only)
Available in 10mg and 50mg Total Dose Vials
Dual-Incretin Therapy for Advanced Weight Loss, Blood Sugar Control & Metabolic Optimization
Formulations (All at 10mg / 1mL Concentration)
-
GL-2 Core 10: 1mL vial containing 10mg total GL-2
-
GL-2 Core 50: 5mL vial containing 50mg total GL-2
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-2 Therapy?
GL-2 is a prescription dual-incretin therapy that activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. These two metabolic pathways work synergistically to regulate appetite, improve insulin sensitivity, enhance satiety, and drive substantial fat loss.
By engaging both incretin systems simultaneously, GL-2 therapy offers greater metabolic impact than single-pathway GL-1 therapy alone and is widely used under clinical supervision for patients seeking more aggressive weight-loss and metabolic optimization.
All GL-2 products provided by PROpeptides require a clinical consultation and prescription from a licensed providerprior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Dual Incretin Activation for Enhanced Fat Loss
GL-2 activates both GLP-1 and GIP receptors, producing complementary effects on appetite suppression, satiety signaling, and energy regulation—resulting in accelerated and sustained fat loss.
SURMOUNT-1 Trial (NEJM, 2022)
– Demonstrated up to 22.5% total body-weight reduction over 72 weeks with dual-incretin therapy at higher doses.
🩸 Blood Sugar Control & Insulin Sensitivity
Dual incretin signaling improves glucose-dependent insulin secretion while reducing inappropriate glucagon release, supporting stable blood sugar control with low hypoglycemia risk.
SURPASS-2 Trial (Lancet, 2021)
– Showed superior HbA1c reduction and weight loss compared to single-pathway GL-1 therapy in patients with metabolic disease.
🧠 Appetite Regulation & Craving Suppression
GL-2 therapy slows gastric emptying, reduces reward-driven eating behavior, and enhances central nervous system satiety signaling.
Min et al., 2020
– Demonstrated modulation of appetite-related neural pathways with dual-incretin activation in both human and preclinical models.
💪 Lean Mass Preservation During Weight Loss
Despite significant fat loss, dual-incretin therapy has been shown to preserve lean muscle mass when paired with adequate protein intake and resistance training.
Heymsfield et al., 2023 (Obesity)
– Lean mass loss was minimized in patients undergoing substantial weight reduction with dual-incretin–based protocols.
⚕️ Clinical Access & Consultation Required
GL-2 therapy is prescription-only and will not be shipped without provider approval.
✔ Telehealth evaluation or established prescription required
✔ Lab testing may be requested (HbA1c, fasting glucose, IGF-1, lipid panel)
✔ Individualized prescription and titration plan
✔ Ongoing provider guidance and follow-up support
💉 Dosing Protocol (Applies to All GL-2 Variants)
Each vial provides 10mg GL-2 per 1mL of solution. Vial size determines total available dose.
| Variant | Volume | Total GL-2 | Estimated Duration |
|---|---|---|---|
| GL-2 Core 10 | 1 mL | 10 mg | ~2–4 weeks |
| GL-2 Core 50 | 5 mL | 50 mg | ~8–12+ weeks |
Typical Starting Dose: 20 units weekly (2 mg)
Titration Strategy:
• Increase by 10 units (1 mg) only after two consecutive weeks with no weight loss and no side effects
• Reduce dose by 10 units if side effects occur, then resume titration as tolerated
Typical Max Dose: 50–60 units weekly (5–6 mg), provider-directed
Route: Subcutaneous injection (abdomen or flank)
Duration: Weekly dosing for 3–6+ months
Stack Compatibility: Commonly paired with KPV, GHK-Cu, or Tesamorelin for inflammation control, body-composition support, and metabolic longevity
📦 What’s Included With Every Order
✔ 1 × GL-2 Molecule vial (Core 10 or Core 50)
✔ Pre-measured bacteriostatic water
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing & titration guide
✔ Telehealth consultation & provider oversight
Need Assistance?
Email: Admin@Propeptides.com
Call/Text: 480-400-6225
🛡️ Next-Level Fat Loss. Dual-Pathway Precision. Clinical Oversight.
GL-2 Core Therapy is designed for patients who need more than foundational GL-1 support. By activating two complementary incretin pathways, GL-2 delivers deeper metabolic change under structured medical supervision.
Start with GL-2 Core 10.
Commit long-term with GL-2 Core 50.
All options include medical consultation and individualized dosing guidance.
Ingredients
GL-2 Molecule (Prescription Only)
Available in 10mg and 50mg Total Dose Vials
Dual-Incretin Therapy for Advanced Weight Loss, Blood Sugar Control & Metabolic Optimization
Formulations (All at 10mg / 1mL Concentration)
-
GL-2 Core 10: 1mL vial containing 10mg total GL-2
-
GL-2 Core 50: 5mL vial containing 50mg total GL-2
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-2 Therapy?
GL-2 is a prescription dual-incretin therapy that activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. These two metabolic pathways work synergistically to regulate appetite, improve insulin sensitivity, enhance satiety, and drive substantial fat loss.
By engaging both incretin systems simultaneously, GL-2 therapy offers greater metabolic impact than single-pathway GL-1 therapy alone and is widely used under clinical supervision for patients seeking more aggressive weight-loss and metabolic optimization.
All GL-2 products provided by PROpeptides require a clinical consultation and prescription from a licensed providerprior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Dual Incretin Activation for Enhanced Fat Loss
GL-2 activates both GLP-1 and GIP receptors, producing complementary effects on appetite suppression, satiety signaling, and energy regulation—resulting in accelerated and sustained fat loss.
SURMOUNT-1 Trial (NEJM, 2022)
– Demonstrated up to 22.5% total body-weight reduction over 72 weeks with dual-incretin therapy at higher doses.
🩸 Blood Sugar Control & Insulin Sensitivity
Dual incretin signaling improves glucose-dependent insulin secretion while reducing inappropriate glucagon release, supporting stable blood sugar control with low hypoglycemia risk.
SURPASS-2 Trial (Lancet, 2021)
– Showed superior HbA1c reduction and weight loss compared to single-pathway GL-1 therapy in patients with metabolic disease.
🧠 Appetite Regulation & Craving Suppression
GL-2 therapy slows gastric emptying, reduces reward-driven eating behavior, and enhances central nervous system satiety signaling.
Min et al., 2020
– Demonstrated modulation of appetite-related neural pathways with dual-incretin activation in both human and preclinical models.
💪 Lean Mass Preservation During Weight Loss
Despite significant fat loss, dual-incretin therapy has been shown to preserve lean muscle mass when paired with adequate protein intake and resistance training.
Heymsfield et al., 2023 (Obesity)
– Lean mass loss was minimized in patients undergoing substantial weight reduction with dual-incretin–based protocols.
⚕️ Clinical Access & Consultation Required
GL-2 therapy is prescription-only and will not be shipped without provider approval.
✔ Telehealth evaluation or established prescription required
✔ Lab testing may be requested (HbA1c, fasting glucose, IGF-1, lipid panel)
✔ Individualized prescription and titration plan
✔ Ongoing provider guidance and follow-up support
💉 Dosing Protocol (Applies to All GL-2 Variants)
Each vial provides 10mg GL-2 per 1mL of solution. Vial size determines total available dose.
| Variant | Volume | Total GL-2 | Estimated Duration |
|---|---|---|---|
| GL-2 Core 10 | 1 mL | 10 mg | ~2–4 weeks |
| GL-2 Core 50 | 5 mL | 50 mg | ~8–12+ weeks |
Typical Starting Dose: 20 units weekly (2 mg)
Titration Strategy:
• Increase by 10 units (1 mg) only after two consecutive weeks with no weight loss and no side effects
• Reduce dose by 10 units if side effects occur, then resume titration as tolerated
Typical Max Dose: 50–60 units weekly (5–6 mg), provider-directed
Route: Subcutaneous injection (abdomen or flank)
Duration: Weekly dosing for 3–6+ months
Stack Compatibility: Commonly paired with KPV, GHK-Cu, or Tesamorelin for inflammation control, body-composition support, and metabolic longevity
📦 What’s Included With Every Order
✔ 1 × GL-2 Molecule vial (Core 10 or Core 50)
✔ Pre-measured bacteriostatic water
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing & titration guide
✔ Telehealth consultation & provider oversight
Need Assistance?
Email: Admin@Propeptides.com
Call/Text: 480-400-6225
🛡️ Next-Level Fat Loss. Dual-Pathway Precision. Clinical Oversight.
GL-2 Core Therapy is designed for patients who need more than foundational GL-1 support. By activating two complementary incretin pathways, GL-2 delivers deeper metabolic change under structured medical supervision.
Start with GL-2 Core 10.
Commit long-term with GL-2 Core 50.
All options include medical consultation and individualized dosing guidance.
Disclaimer
GL-2 Molecule (Prescription Only)
Available in 10mg and 50mg Total Dose Vials
Dual-Incretin Therapy for Advanced Weight Loss, Blood Sugar Control & Metabolic Optimization
Formulations (All at 10mg / 1mL Concentration)
-
GL-2 Core 10: 1mL vial containing 10mg total GL-2
-
GL-2 Core 50: 5mL vial containing 50mg total GL-2
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-2 Therapy?
GL-2 is a prescription dual-incretin therapy that activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. These two metabolic pathways work synergistically to regulate appetite, improve insulin sensitivity, enhance satiety, and drive substantial fat loss.
By engaging both incretin systems simultaneously, GL-2 therapy offers greater metabolic impact than single-pathway GL-1 therapy alone and is widely used under clinical supervision for patients seeking more aggressive weight-loss and metabolic optimization.
All GL-2 products provided by PROpeptides require a clinical consultation and prescription from a licensed providerprior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Dual Incretin Activation for Enhanced Fat Loss
GL-2 activates both GLP-1 and GIP receptors, producing complementary effects on appetite suppression, satiety signaling, and energy regulation—resulting in accelerated and sustained fat loss.
SURMOUNT-1 Trial (NEJM, 2022)
– Demonstrated up to 22.5% total body-weight reduction over 72 weeks with dual-incretin therapy at higher doses.
🩸 Blood Sugar Control & Insulin Sensitivity
Dual incretin signaling improves glucose-dependent insulin secretion while reducing inappropriate glucagon release, supporting stable blood sugar control with low hypoglycemia risk.
SURPASS-2 Trial (Lancet, 2021)
– Showed superior HbA1c reduction and weight loss compared to single-pathway GL-1 therapy in patients with metabolic disease.
🧠 Appetite Regulation & Craving Suppression
GL-2 therapy slows gastric emptying, reduces reward-driven eating behavior, and enhances central nervous system satiety signaling.
Min et al., 2020
– Demonstrated modulation of appetite-related neural pathways with dual-incretin activation in both human and preclinical models.
💪 Lean Mass Preservation During Weight Loss
Despite significant fat loss, dual-incretin therapy has been shown to preserve lean muscle mass when paired with adequate protein intake and resistance training.
Heymsfield et al., 2023 (Obesity)
– Lean mass loss was minimized in patients undergoing substantial weight reduction with dual-incretin–based protocols.
⚕️ Clinical Access & Consultation Required
GL-2 therapy is prescription-only and will not be shipped without provider approval.
✔ Telehealth evaluation or established prescription required
✔ Lab testing may be requested (HbA1c, fasting glucose, IGF-1, lipid panel)
✔ Individualized prescription and titration plan
✔ Ongoing provider guidance and follow-up support
💉 Dosing Protocol (Applies to All GL-2 Variants)
Each vial provides 10mg GL-2 per 1mL of solution. Vial size determines total available dose.
| Variant | Volume | Total GL-2 | Estimated Duration |
|---|---|---|---|
| GL-2 Core 10 | 1 mL | 10 mg | ~2–4 weeks |
| GL-2 Core 50 | 5 mL | 50 mg | ~8–12+ weeks |
Typical Starting Dose: 20 units weekly (2 mg)
Titration Strategy:
• Increase by 10 units (1 mg) only after two consecutive weeks with no weight loss and no side effects
• Reduce dose by 10 units if side effects occur, then resume titration as tolerated
Typical Max Dose: 50–60 units weekly (5–6 mg), provider-directed
Route: Subcutaneous injection (abdomen or flank)
Duration: Weekly dosing for 3–6+ months
Stack Compatibility: Commonly paired with KPV, GHK-Cu, or Tesamorelin for inflammation control, body-composition support, and metabolic longevity
📦 What’s Included With Every Order
✔ 1 × GL-2 Molecule vial (Core 10 or Core 50)
✔ Pre-measured bacteriostatic water
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing & titration guide
✔ Telehealth consultation & provider oversight
Need Assistance?
Email: Admin@Propeptides.com
Call/Text: 480-400-6225
🛡️ Next-Level Fat Loss. Dual-Pathway Precision. Clinical Oversight.
GL-2 Core Therapy is designed for patients who need more than foundational GL-1 support. By activating two complementary incretin pathways, GL-2 delivers deeper metabolic change under structured medical supervision.
Start with GL-2 Core 10.
Commit long-term with GL-2 Core 50.
All options include medical consultation and individualized dosing guidance.
